Comprehensive Stock Comparison
Compare Seres Therapeutics, Inc. (MCRB) vs Vertex Pharmaceuticals Incorporated (VRTX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  MCRB | 448.4% revenue growth vs VRTX's 8.9% |
| Quality / Margins | MCRB | 15.4% net margin vs VRTX's 31.3% |
| Stability / Safety |  VRTX | Beta 0.44 vs MCRB's 1.21, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | VRTX | -2.0% vs MCRB's -41.7% |
| Efficiency (ROA) | VRTX | 14.8% ROA vs MCRB's 3.8%, ROIC 22.8% vs -180.9% |
Who Each Stock Is For
Income & stability
VRTXbeta 0.44
Growth exposure
MCRBRev growth 448.4%, EPS growth -6.2%
Long-term compounding (10Y)
VRTX429.7% 10Y total return vs MCRB's -98.4%
Sleep-well-at-night portfolio
VRTXLower volatility, beta 0.44, Low D/E 19.8%, current ratio 2.90x
Defensive / Recession hedge
VRTXBeta 0.44, current ratio 2.90x
Business Model
What each company does and how it makes money
Seres Therapeutics is a microbiome therapeutics company developing bacterial consortia treatments for serious diseases. It generates revenue primarily through collaboration agreements and milestone payments — notably with Nestlé Health Science — while advancing its lead candidate SER-109 toward FDA approval for recurrent C. difficile infection. The company's key advantage is its proprietary platform for rationally designing bacterial consortia that functionally interact with human biology, creating a technical moat in the emerging microbiome therapeutics field.
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing transformative medicines for serious diseases, with its flagship franchise targeting cystic fibrosis. It generates nearly all its revenue from CF therapies — primarily Trikafta/Kaftrio — while building a pipeline in pain, kidney disease, and type 1 diabetes. Its moat stems from deep scientific expertise in CFTR biology and a dominant, near-monopoly position in the CF treatment market.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
VRTX 4MCRB 1VRTX3/5 metricsMCRB2/2 metricsVRTX6/8 metricsVRTX6/6 metricsVRTX2/2 metricsVRTX leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). MCRB leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
VRTX is the larger business by revenue, generating $11.7B annually — 33399.7x MCRB's $351,000. Profitability is closely matched — net margins range from 15.4% (MCRB) to 31.3% (VRTX).
| Metric | MCRBSeres Therapeutic… | VRTXVertex Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $351,000 | $11.7B |
| EBITDAEarnings before interest/tax | -$99M | $4.2B |
| Net IncomeAfter-tax profit | $5M | $3.7B |
| Free Cash FlowCash after capex | -$23M | $3.3B |
| Gross MarginGross profit ÷ Revenue | -50.1% | +86.3% |
| Operating MarginEBIT ÷ Revenue | -294.7% | +34.1% |
| Net MarginNet income ÷ Revenue | +15.4% | +31.3% |
| FCF MarginFCF ÷ Revenue | -66.6% | +28.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +11.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +112.3% | +4.7% |
Valuation Metrics
| Metric | MCRBSeres Therapeutic… | VRTXVertex Pharmaceut… |
|---|---|---|
| Market CapShares × price | $77M | $120.4B |
| Enterprise ValueMkt cap + debt − cash | $137M | $119.0B |
| Trailing P/EPrice ÷ TTM EPS | -0.46x | 30.93x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 24.47x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.73x |
| EV / EBITDAEnterprise value multiple | — | 25.38x |
| Price / SalesMarket cap ÷ Revenue | — | 10.03x |
| Price / BookPrice ÷ Book value/share | 4.92x | 6.55x |
| Price / FCFMarket cap ÷ FCF | — | 37.68x |
Profitability & Efficiency
VRTX delivers a 21.2% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $12 for MCRB. VRTX carries lower financial leverage with a 0.20x debt-to-equity ratio, signaling a more conservative balance sheet compared to MCRB's 6.65x. On the Piotroski fundamental quality scale (0–9), VRTX scores 5/9 vs MCRB's 2/9, reflecting solid financial health.
| Metric | MCRBSeres Therapeutic… | VRTXVertex Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | +12.3% | +21.2% |
| ROA (TTM)Return on assets | +3.8% | +14.8% |
| ROICReturn on invested capital | -180.9% | +22.8% |
| ROCEReturn on capital employed | -67.7% | +23.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | 6.65x | 0.20x |
| Net DebtTotal debt minus cash | $61M | $3.7B |
| Cash & Equiv.Liquid assets | $31M | $5.1B |
| Total DebtShort + long-term debt | $92M | $3.7B |
| Interest CoverageEBIT ÷ Interest expense | — | 348.55x |
Total Returns (with DRIP)
A $10,000 investment in VRTX five years ago would be worth $22,732 today (with dividends reinvested), compared to $247 for MCRB. Over the past 12 months, VRTX leads with a -2.0% total return vs MCRB's -41.7%. The 3-year compound annual growth rate (CAGR) favors VRTX at 17.7% vs MCRB's -56.4% — a key indicator of consistent wealth creation.
| Metric | MCRBSeres Therapeutic… | VRTXVertex Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -42.4% | +4.8% |
| 1-Year ReturnPast 12 months | -41.7% | -2.0% |
| 3-Year ReturnCumulative with dividends | -91.7% | +63.1% |
| 5-Year ReturnCumulative with dividends | -97.5% | +127.3% |
| 10-Year ReturnCumulative with dividends | -98.4% | +429.7% |
| CAGR (3Y)Annualised 3-year return | -56.4% | +17.7% |
Risk & Volatility
VRTX is the less volatile stock with a 0.44 beta — it tends to amplify market swings less than MCRB's 1.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VRTX currently trades 91.2% from its 52-week high vs MCRB's 29.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MCRBSeres Therapeutic… | VRTXVertex Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.21x | 0.44x |
| 52-Week HighHighest price in past year | $29.98 | $519.68 |
| 52-Week LowLowest price in past year | $6.53 | $362.50 |
| % of 52W HighCurrent price vs 52-week peak | +29.1% | +91.2% |
| RSI (14)Momentum oscillator 0–100 | 30.8 | 61.8 |
| Avg Volume (50D)Average daily shares traded | 63K | 1.2M |
Analyst Outlook
Wall Street rates MCRB as "Buy" and VRTX as "Buy". Consensus price targets imply 15.0% upside for VRTX (target: $545) vs -85.7% for MCRB (target: $1).
| Metric | MCRBSeres Therapeutic… | VRTXVertex Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $1.25 | $545.08 |
| # AnalystsCovering analysts | 18 | 55 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| Seres Therapeutics,… (MCRB) | 100 | 11.93 | -88.1% |
| Vertex Pharmaceutic… (VRTX) | 100 | 210.14 | +110.1% |
Vertex Pharmaceutic… (VRTX) returned +127% over 5 years vs Seres Therapeutics,… (MCRB)'s -98%. A $10,000 investment in VRTX 5 years ago would be worth $22,732 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Seres Therapeutics,… (MCRB) | $22M | $0.00 | -100.0% |
| Vertex Pharmaceutic… (VRTX) | $1.7B | $12.0B | +605.1% |
Vertex Pharmaceuticals Incorporated's revenue grew from $1.7B (2016) to $12.0B (2025) — a 24.2% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Seres Therapeutics,… (MCRB) | -4.2% | -45.2% | -975.5% |
| Vertex Pharmaceutic… (VRTX) | -6.6% | 32.9% | +600.4% |
Vertex Pharmaceuticals Incorporated's net margin went from -7% (2016) to 33% (2025).
Chart 4P/E Ratio History — 8 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Vertex Pharmaceutic… (VRTX) | 144.1 | 29.6 | -79.5% |
Vertex Pharmaceuticals Incorporated has traded in a 21x–144x P/E range over 8 years; current trailing P/E is ~31x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Seres Therapeutics,… (MCRB) | -46 | -18.86 | +59.0% |
| Vertex Pharmaceutic… (VRTX) | -0.46 | 15.32 | +3430.4% |
Vertex Pharmaceuticals Incorporated's EPS grew from $-0.46 (2016) to $15.32 (2025).
Chart 6Free Cash Flow — 5 Years
Seres Therapeutics, Inc. generated $-149M FCF in 2024 (-5077% vs 2021). Vertex Pharmaceuticals Incorporated generated $3B FCF in 2025 (+33% vs 2021).
MCRB vs VRTX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MCRB or VRTX a better buy right now?
Vertex Pharmaceuticals Incorporated (VRTX) offers the better valuation at 30.9x trailing P/E (24.5x forward), making it the more compelling value choice. Analysts rate Seres Therapeutics, Inc. (MCRB) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MCRB or VRTX?
Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +127.3%, compared to -97.5% for Seres Therapeutics, Inc. (MCRB). A $10,000 investment in VRTX five years ago would be worth approximately $23K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VRTX returned +429.7% versus MCRB's -98.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MCRB or VRTX?
By beta (market sensitivity over 5 years), Vertex Pharmaceuticals Incorporated (VRTX) is the lower-risk stock at 0.44β versus Seres Therapeutics, Inc.'s 1.21β — meaning MCRB is approximately 175% more volatile than VRTX relative to the S&P 500. On balance sheet safety, Vertex Pharmaceuticals Incorporated (VRTX) carries a lower debt/equity ratio of 20% versus 7% for Seres Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — MCRB or VRTX?
Seres Therapeutics, Inc. (MCRB) is the more profitable company, earning 1537% net margin versus 32.9% for Vertex Pharmaceuticals Incorporated — meaning it keeps 1537% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39.1% versus -294.7% for MCRB. At the gross margin level — before operating expenses — VRTX leads at 86.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is MCRB or VRTX more undervalued right now?
Analyst consensus price targets imply the most upside for VRTX: 15.0% to $545.08.
06Which pays a better dividend — MCRB or VRTX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MCRB or VRTX better for a retirement portfolio?
For long-horizon retirement investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.44), +429.7% 10Y return). Both have compounded well over 10 years (VRTX: +429.7%, MCRB: -98.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MCRB and VRTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.